Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression.
about
Developmentally restricted genetic determinants of human arsenic metabolism: association between urinary methylated arsenic and CYT19 polymorphisms in children.Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).Arsenic trioxide - An old drug rediscovered.Downregulation of hTERT: an important As2O3 induced mechanism of apoptosis in myelodysplastic syndromeArsenic trioxide: safety issues and their management.Differential surface expression of CD18 and CD44 by neutrophils in bone marrow and spleen contributed to the neutrophilia in thalidomide-treated female B6C3F1 miceArsenic trioxide: an anti cancer missile with multiple warheads.Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes.Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer.Molecular mechanisms involved in the progression of myelodysplastic syndrome.Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis.Diagnostic challenges in the myelodysplastic syndromes: the current and future role of genetic and immunophenotypic studies.The Synergistic Effects of Decitabine Combined with Arsenic Trioxide (ATO) in the Human Myelodysplastic Syndrome Cell Line SKM-1.Inorganic phosphate-triggered release of anti-cancer arsenic trioxide from a self-delivery system: an in vitro and in vivo study.Point mutations in two EVI1 Zn fingers abolish EVI1-GATA1 interaction and allow erythroid differentiation of murine bone marrow cells.Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism.Therapeutic spectrum in the treatment of myelodysplastic syndromes.Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient.EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia.Association of 3q21q26 syndrome and late-appearing Philadelphia chromosome in acute myeloid leukemia.Molecular analysis of more than 140 gene fusion variants and aberrant activation of EVI1 and TLX1 in hematological malignancies.
P2860
Q24536026-FF7BF7BF-93B2-49AE-BF7F-4AFF34A6D265Q33920750-F758C155-AC34-421D-A273-92D3CB2A848DQ34054167-B733D5F8-619E-4F4F-8745-78FEC0D7253CQ34557051-14E4CD2D-5136-4CF5-BDFB-D3BDD4F254C9Q34588761-BCD8F43B-8D0D-4507-8E85-E873EEF875EBQ35757592-30207835-7E41-45E6-ADD4-5E05E7AE1EE9Q36194579-77B8D5C9-4CBC-4604-8E4E-1C440CCC610CQ37486703-65D1DC07-AA3B-47D0-B078-4760E96BA99FQ37580699-9BD9F366-46CD-4603-B6FE-8EBBA4BCC89BQ37707390-8132376A-25FC-489C-B0D1-A26B017AE5A3Q38001764-C23B1208-4889-47B5-9627-494A2BE24719Q38089064-AD59F640-B993-4ED2-BB63-92F9FD22CF52Q38733061-64F48477-D312-474D-BD98-5E910CD68DD5Q38789790-82CB7E23-FC8D-423C-B106-131FEA196755Q39129759-D8B96F5A-B26C-45C7-A8CD-733553AC8796Q40009277-CE20BA07-C34E-46DC-95B1-E073B90E34A3Q40464419-894E14B6-ED59-447A-B398-6338C94E3A11Q41875544-17A6F8B9-3AFC-4AD9-94AC-DF670EE23375Q43486412-135BE97F-EE43-4C18-B1AF-E1EEE8EF7255Q46956230-F534EBBA-FB82-4252-A176-3948708554E1Q47988320-6EFFF899-9C76-4881-850A-A4A2C6F393C7
P2860
Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Arsenic trioxide and thalidomi ...... h pre-therapy EVI1 expression.
@en
Arsenic trioxide and thalidomi ...... h pre-therapy EVI1 expression.
@nl
type
label
Arsenic trioxide and thalidomi ...... h pre-therapy EVI1 expression.
@en
Arsenic trioxide and thalidomi ...... h pre-therapy EVI1 expression.
@nl
prefLabel
Arsenic trioxide and thalidomi ...... h pre-therapy EVI1 expression.
@en
Arsenic trioxide and thalidomi ...... h pre-therapy EVI1 expression.
@nl
P2093
P1433
P1476
Arsenic trioxide and thalidomi ...... gh pre-therapy EVI1 expression
@en
P2093
Anna Candoni
Donglan Li
Giuseppina Nucifora
Hassan Pervaiz
J Alejandro Gallegos
Laurie Lisak
M Imran Alvi
Mehnaz Imran
Muhammad Mumtaz
P304
P356
10.1016/J.LEUKRES.2003.11.018
P577
2004-08-01T00:00:00Z